Biohaven Ltd. · NYSE:BHVN
Biohaven — ABI Conference April 2024
13 slides from Biohaven's conference presentation, Apr 15, 2024
Slide 1: Biohaven's New Approach to Immune-Mediated Diseases Using Yale Science
BIOHAVEN’S NEW APPROACH TO IMMUNE- MEDIATED DISEASES USING YALE SCIENCE FOR TARGETED EXTRACELLULAR PROTEIN DEGRADATION David Spiegel, M.D., Ph.D. Professor of Chemistry and Pharmacology, Yale University Scientific Advisor, Biohaven
Slide 2: Spiegel Research Group
SPIEGEL RESEARCH GROUP
Slide 3: Protein Aging, ASGPR: The Idea, 2015
PROTEIN AGING PROTEIN ASGPR ASGPR asialoglycoprotein receptor IDEA! 2015
Slide 4: First MoDE experiments were effective
First MoDE experiments were effective 21 OCT 2015 23 NOV 2015 16 SEP 2016 9 APR 2018 3 JAN 2019 29 JUL 2020 17 SEP 2021 began experiments filed U.S. patent filed U.S. patent
Slide 5: MoDE Platform: Molecular Degraders of Extracellular Proteins
TARGET BINDER STABLE LINKER ASGPR BINDER COMPOUND LIBRARY BINDER COMPOUND LIBRARYMoDEs® Molecule MoDE PLATFORM MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS TRANSFORMATIONAL DRUG PLATFORM ™
Slide 6: Extracellular MoDEs Degrader Redirects Pathogenic Proteins to the Liver
EXTRACELLULAR MoDEs® DEGRADER REDIRECTS PATHOGENIC PROTEINS TO THE LIVER FOR TARGETED, EFFICIENT AND EFFECTIVE REMOVAL
Slide 7: BHV-1300: Shows Potential for Superiority Over FcRn Inhibitors
BHV-1300: SHOWS POTENTIAL FOR SUPERIORITY OVER FcRn INHIBITORS 0 50 100 150 0 5 10 15 % Ig G , b as el in e Days after start of infusion 10 mg/kg 75 mg/kg 250 mg/kg Vehicle BHV-1300 NHP Pharmacodynamics 2–3 days to reach 80% lowering Efgartigimod NHP Pharmacodynamics 5–7 days to reach 50% lowering 0
Slide 8: BHV-1300: Unique Properties Matched to Chronic Indications
BHV-1300: UNIQUE PROPERTIES MATCHED TO CHRONIC INDICATIONS APRIL 2024 ABI CONFERENCE 8 BHV-1300 Preclinical Pharmacodynamics (Multiple Dose) Dose Administered 60% LOWERING 90% LOWERING KEY POINTS • Depth of lowering reaches 90% after second dose • Depth of lowering is tunable: easily adjusted by fre
Slide 9: BHV-1300: Pharmacodynamic Data Supports Co-administration with mAbs
BHV-1300: PHARMACODYNAMIC DATA SUPPORTS ABILITY TO CO-ADMINISTER WITH mAbs REPRESENTING A POTENTIAL ADVANCEMENT TO FcRn INHIBITORS APRIL 2024 ABI CONFERENCE 9 * Adapted from BLA 761154, IND 116471, Study no. r-fkb327-01. Humira 3 mg/kg SC, After a 30 mg/kg SC Dose of BHV-1300 to NHP Time (days) M ea
Slide 10: IgG Lowering with BHV-1300 Offers Significant Potential Benefits Over FcRn Inhibitors
IgG LOWERING WITH BHV-1300 OFFERS SIGNIFICANT POTENTIAL BENEFITS OVER FcRn INHIBITORS FcRn Inhibitors BHV-1300 MoDE™ FcRn, neonatal Fc receptor; IgG, immunoglobulin; IV, intravenous; SC, subcutaneous. ASGPR DEGRADATION TARGET BIFUNCTIONAL MoDE® DEGRADER HEPATOCYTE APRIL 2024 ABI CONFERENCE 10 No Imp
Slide 11: MoDE Summary: A First-in-Class Platform
MoDE™ SUMMARY A FIRST-IN-CLASS PLATFORM TO ADDRESS UNMET NEED IN ANTIBODY-MEDIATED DISEASES April 2024 ABI Conference 11 FcRn, neonatal Fc receptor; IgG, immunoglobulin. Selective extracellular protein degradation provides many predicted and potential advantages Rapid onset of IgG lowering Depth of
Slide 12: Study BHV1300-101: Preliminary First-in-Human SAD Study Update
Biohaven’s Study BHV1300-101: PRELIMINARY FIRST-IN-HUMAN SINGLE ASCENDING DOSE (SAD) STUDY UPDATE APRIL 2024 ABI CONFERENCE 12 * Preliminary data from Study 1300-101 is from an ongoing study and subject to change (database not yet cleaned or locked) **IgG1-4 analyzed at Mayo Clinic Laboratories, Roc
Slide 13: Thank You!
THANK YOU! CATCH UP ON THE LATEST NEWS AT THE SPIEGEL RESEARCH GROUP KEEP UP TO DATE ON BIOHAVEN'S DEGRADER PROGRAMS